Insmed Inc (INSM)

[rstor1]

Io_io and Chap

Good points.

And a futher elaboration on Chap's point:
+++there is often a benefit in the potential shortening of timelines for further research with the added capital and research infrastructure a partner can bring+++

The future revenue stream is limited by the remaining patent life. This is less true in biologics than in small molecules, but the advent of generic biologics is not taht far away.

If you reduce time-to-market in other indications, it means more years of IP protection at peak earnings (back end) for the drug.

I want to be clear that I am not necessarily advocating a partnership for every indication or for evey geo area. The point that I am making is that it's not a slam-dunk decision.

Regards,
Bob